Beyond Ozempic breath: A U of T Dentistry researcher examines GLP-1s and oral health By Diane Peters At his practice in North York, U of T Dentistry associate professor Aviv Ouanounou often treats patients with complex health conditions such as diabetes, cardiovascular disease and obesity
Semaglutide GLP-1 is an FDA-approved option for weight loss that works by regulating appetite and supporting healthy metabolic function
Notably, GLP-1RAs may be more effective in patients at high risk for AF, such as those with T2DM
He and other experts are working on subsequent research examining the effects of different diabetes treatments on other health outcomes and concerns, including a patients risk of cancer, blindness or amputation
Akkermansia is also a beneficial gut bacteria that clinical research shows improves insulin sensitivity, reduces insulin levels, and supports healthy cholesterol